An observational study in Heart Failure, sponsored by Cordio Medical. Completed at 7 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Cordio Medical · Observational
Among 182 studies in Heart Failure with a site in Israel — 23 open to participants now, 28 under way, 7 of them phase 3. Heart Failure · Israel.
Among the 182 studies in Heart Failure with a site in Israel, this one is the 16th largest by enrollment of the 46 observational ones, is one of 10 that started in 2015, is one of 46 observational ones, and was the 128th registered.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's enrollment of 427 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Browse Heart Failure studies →23 of the 182 studies in Heart Failure with a site in Israel are open now, in 12 countries. Each count lists the studies.
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →182 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 10 started in 2015.
Median enrollment 260 across the 134 interventional studies, 150 across the 46 observational. Of the 116 that completed or were terminated, 43 (37%) have results posted.
116 of 182 have an industry lead sponsor. The 10 most frequent:
Cordio Medical is the lead sponsor of 6 studies on the registry; none are open to participants now.
Cordio Medical has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Failure with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06682910Microtech Medical Technologies, LtdAssessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation | 2026-11 |
| NCT06851949Cardiac SuccessVsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure | 2026-12 |
| NCT06122779Bristol-Myers SquibbStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | 2026-12-14 |
| NCT07601724Itshak AmsalemThe Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure | 2027-01 |
Among the 182 studies in Heart Failure with a site in Israel, from their registry updates:
This is a multi-center, observational, non-interventional, prospective, Single-arm, open study for database establishment for R\&D purposes. R\&D data will be analyzed retrospectively in order to validate algorithm efficacy.
The study will be conducted in the following settings: outpatinets clinics
Patients with NYHA 2-3. All patients must meet eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cordio R\&D database to develop the Cordio System
Device: Cordio System
App, cloud and web device
R&D Database & Efficiency
Building R\&D recording database and retrospectively Cordio System needs to reach correlation between the system generated alerts to HF exacerbation
Time frame: 2 years
Usability
Questionnaires with SUS scale and specific app questions in order to assess the app usability
Time frame: 2 years
SADE Endpoint
Demonstration of the safe use of the device by overall incidence of device related adverse events.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2015 to primary completion in Apr 2024, 102 months.
Of 182 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's 102 months is above that.
Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Apr 2022 → Apr 2024 and completion Apr 2022 → Apr 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cordio Medical